A1SN34.SA Ascendis Pharma A/S

Healthcare Biotechnology Sao Paulo Exchange
88.11 BRL
Close of Nov 5, 2026
70.00 94.05
Market cap
BRL 5.80B
P/E
1.3x
P/B
0.67x
ROE
116.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is A1SN34.SA undervalued?

Graham number

The Graham number of Ascendis Pharma A/S cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ascendis Pharma A/S fundamental analysis

No fundamental analysis for Ascendis Pharma A/S yet.

Ascendis Pharma A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease produc…

Full company profile